Abstract
BackgroundAnifrolumab is a fully human anti–interferon-α receptor monoclonal antibody in Phase III development for systemic lupus erythematosus (SLE). In Phase IIb trials, intravenous (IV) anifrolumab (300 mg every 4 weeks)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have